Transgenic Mouse Model of Tauopathies with Glial Pathology and Nervous System Degeneration  by Higuchi, Makoto et al.
Neuron, Vol. 35, 433–446, August 1, 2002, Copyright 2002 by Cell Press
Transgenic Mouse Model of Tauopathies with
Glial Pathology and Nervous System Degeneration
levels of tau in the CNS (Hong et al., 1998; Hutton et al.
1998; D’Souza et al., 1999).
Compelling evidence for tau-induced neurogenera-
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1Center for Neurodegenerative Disease Research tion also comes from studies of sporadic tauopathies,
such as PSP, CBD, and PiD, wherein abundant filamen-Department of Pathology and Laboratory Medicine
University of Pennsylvania School of Medicine tous tau pathology and brain degeneration occur in the
absence of other lesions, and individuals with FTDP-17Philadelphia, Pennsylvania 19104
2 Department of Biomedical Sciences exhibit phenotypes similar to PSP, CBD, PSG, or PiD
(McKhann et al., 2001). Significantly, the filamentousE.K. Shriver Center for Mental Retardation
Waltham, Massachusetts 02254 tau pathologies in FTDs are not restricted to neuropil
threads and neurofibrillary tangles (NFTs), since abun-
dant glial fibrillary pathology (e.g., astrocytic plaques,
tufted astrocytes, or coiled bodies in oligodendrocytes)Summary
also occurs (Nishimura et al., 1992; Feany and Dickson,
1995; Dickson et al., 1996; Yamazaki et al., 1994), andFrontotemporal dementias (FTDs), including cortico-
this may be more abundant than neuronal tau pathologybasal degeneration (CBD) and progressive supranu-
(Forman et al., 2002; Zhukareva et al., 2002).clear palsy (PSP), are neurodegenerative tauopathies
Early efforts to develop transgenic (Tg) mouse modelscharacterized by widespread CNS neuronal and glial
of tauopathies focused on replicating neuronal tau pa-tau pathologies, but there are no tau transgenic (Tg)
thology by overexpressing human tau proteins in neu-mice that model neurodegeneration with glia tau le-
rons which lead to neuronal and axonal degenerationsions. Thus, we generated Tg mice overexpressing
with muscle weaknesses (Ishihara et al., 1999, 2001;human tau in neurons and glia. No neuronal tau aggre-
Spittaels et al., 1999; Probst et al., 2000). Tau Tg micegates were detected, but old mice developed Thi-
overexpressing human tau with the P301L FTDP-17 mu-oflavin S- and Gallyas-positive glial tau pathology
tation also were produced, and they developed a moreresembling CBD astrocytic plaques. Tau-immunore-
severe phenotype than wild-type (WT) tau Tg animalsactive and Gallyas-positive oligodendroglial coiled
(Lewis et al., 2000; Go¨tz et al., 2001a). Thus, overexpres-bodies (similar to CBD and PSP), glial degeneration,
sion of either WT or mutant human tau in neurons clearlyand motor deficits were associated with age-depen-
causes neurodegeneration in Tg mice. However, sincedent accumulations of insoluble hyperphosphorylated
glial tau pathology is a prominent neuropathological fea-human tau and tau immunopositive filaments in de-
ture of FTDP-17, PSP, CBD, PSG, and PiD, current ani-generating glial cells. Thus, tau-positive glial lesions
mal models do not elucidate the contribution of thissimilar to human FTDs occur in these Tg mice, and
pathology to neurodegeneration in these disorders.these pathologies are linked to glial and axonal degen-
To address this, we developed Tg mice overexpress-eration.
ing human tau in both neurons and glia. These mice did
not develop neuronal tau inclusions, but they formed
Introduction glial tau pathologies recapitulating those found in hu-
man tauopathies.
Filamentous tau inclusions, accompanied by extensive
neuron loss and gliosis, are the neuropathological hall- Results
marks of neurodegenerative tauopathies (Lee et al.,
2001). Prototypical tauopathies are exemplified by fron- Generation of Tg Mice Overexpressing
totemporal dementia with parkinsonism linked to chro- Three-Repeat Human Tau Isoforms
mosome 17 (FTDP-17), corticobasal degeneration (CBD), Transgenic mice that overexpressed all three human tau
progressive supranuclear palsy (PSP), progressive sub- isoforms with 3 microtubule (MT) binding repeats (3RT)
cortical gliosis (PSG), and Pick’s disease (PiD). Like all were generated using a minigene construct combined
tauopathies, FTDP-17, PSP, CBD, PSG, and PiD are with the mouse T1 -tubulin promoter (Figure 1A). The
characterized by numerous inclusions formed by aggre- minigene contained complete sequences of human CNS
gated paired helical filaments (PHFs) and/or straight fila- tau exons as well as modified sequences of introns that
ments comprised of aberrantly phosphorylated tau pro- flanked exons 2 and 3 to drive expression of the down-
teins (PHF-tau) throughout the CNS (Lee et al., 2001). stream gene construct in the murine CNS (Gloster et al.,
The discovery of tau gene mutations in FTDP-17 kin- 1994). Three founders (#13, #14, and #22) were obtained
dreds provided unequivocal evidence that tau abnor- that expressed the human tau proteins stably (Figure
malities cause neurodegenerative disease (Clark et al., 1B). One of the founders (line 14) with the highest trans-
1998; Hutton et al., 1998, Poorkaj et al., 1998, Spillantini gene copy number and highest tau protein expression
et al., 1998a). Intronic and exonic FTDP-17 tau gene was propagated and used for the analyses in this paper.
mutations cause disease by altering the functions or As shown in Figure 1C, expression of tau proteins in
both Tg and WT mice reached a stable state at 28 days
of age, and quantification of the signal intensity indi-3 Correspondence: vmylee@mail.med.upenn.edu
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Figure 1. Structure of the Transgene and Ex-
pression of Endogenous Mouse Tau and
Transgenic Human Tau in WT and Tg Mice
(A) Schematic representation of the expres-
sion construct used to generate T1-3RT tau
transgenic mouse.
(B) Western blot analysis of dephosphory-
lated tau proteins in Tg mice from lines 13,
14, and 22 by using T14 antibody. Line 14 has
the highest expression level of the transgenic
tau, and line 13 has the lowest.
(C) Immunoblot for non-dephosphorylated
tau proteins extracted from the neocortical
samples of WT and Tg mice at different ages.
Both mouse and human tau proteins were
detected by using the polyclonal antibodies
17026 and quantified with 125I-labeled sec-
ondary antibodies.
(D) Immunoblot analysis of transgenic human
and endogenous mouse tau expressions in the
brain and spinal cord of WT and single Tg mice
as well as bigenic mice without endogenous
mouse tau (i.e., T1-3RT Tg  tau-KO). All
samples were dephosphorylated using alka-
line phosphatase before being loaded on
gels. Transgenic human and endogenous
mouse tau proteins were detected by using
species-specific mAbs T14 and T49, respec-
tively. The top bands in the rightmost blots
were endogenous mouse “big” tau found in
the peripheral nervous system.
(E) Developmental changes of human and mouse tau expressions demonstrated by immunoblots using dephosphorylated tau protein samples
from mouse neocortex and spinal cord. Endogenous mouse tau isoforms in WT (upper panel) and Tg (middle panel) mice were detected by
the mAb T49, and transgenic human tau isoforms in Tg mice (lower panel) were analyzed with the mAb T14.
cated that the expression level of transgenic human tau postnatal development, but 4R tau isoforms increased
after birth until 1 month of age, and this pattern was notwas 5.5-fold higher than that of endogenous mouse tau
in adult Tg mice. These T1-3RT Tg mice were crossbred different from that of WT mice (upper and middle panels
in Figure 1E). Transgenic human tau isoforms also in-with tau-KO mice to generate mice that expressed only
human tau isoforms without endogenous mouse tau creased during postnatal development until 1 month old,
but unlike endogenous mouse tau, a predominance of(TgKO mice). Figure 1D shows the tau isoform compo-
sition in WT mice and Tg mice with (single Tg mice) and human 3R0N tau was not observed in early postnatal
development (lower panel in Figure 1E).without (Tg  KO mice) endogenous mouse tau. The
levels of human tau isoforms with no amino terminal
insert (3R0N), one amino terminal insert (3R1N), and two Tg Mice Develop Glial Tau Inclusions Similar
to Those in Human Tauopathiesamino terminal inserts (3R2N) as percentages of total
human tau were 7%, 12%, and 81%, respectively, in the The distribution of tau proteins was next examined in
the T1-3RT Tg mice, and strong tau immunoreactivitybrain, and 8%, 16%, and 76%, respectively, in the spinal
cord, in both single Tg and Tg  KO mice. The levels was detected in both neurons and glia. Most of the CNS
neurons were immunostained to some extent with anti-of mouse 4 MT binding repeat tau isoforms (4R0N, 4R1N,
4R2N) as percentages of total mouse tau were 57%, tau antibodies, and neuronal tau immunoreactivities
were observed in the brain stem and spinal cord (Figures19%, and 24%, respectively, in the brain, and 41%, 16%,
and 43%, respectively, in the spinal cord, in WT and 2A and 2B). Although older Tg mice showed more in-
tense neuronal tau staining than young mice, no tausingle Tg mice. These data indicate that although the
splicing patterns of tau isoforms in the brain and spinal aggregates in the form of perikaryal inclusions, spher-
oids, or dystrophic neurites were detected. Tau-positivecord are different, there are greater differences in the
splicing of the amino-terminal inserts between the trans- glial cells with small cytoplasm and a few processes
were observed in the white matter of the brain and moregenic human tau and endogenous mouse tau. The data
also suggest that the presence or absence of the trans- frequently in the brain stem and gray and white matters
of the spinal cord (Figures 2A, 2C, and 2D). These cellsgenic human tau does not influence the splicing of the
endogenous mouse tau and that the splicing of human were morphologically identical to oligodendrocytes, and
the colocalization of tau and 2,3-cyclic nucleotide 3-tau in Tg mice is independent of the endogenous
mouse tau. phosphodiesterase (CNP), a marker for oligodendro-
cytes, by double immunofluorescence staining con-Developmental changes of human and mouse tau pro-
tein expression were also examined in T1-3RT Tg mice firmed their identity (Figures 2E–2G). At 1 month of age,
approximately 10% of CNP-positive oligodendrocytes(Figure 1E). The isoform composition of endogenous
mouse tau showed predominantly 3R0N tau in the early overexpressed tau proteins, and the number of tau-
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Figure 2. Accumulation of Tau Proteins in Neurons and Glial Cells of 12-Month-Old Tg Mouse Spinal Cord and Ventral Roots
(A) Immunohistochemical analysis with tau antibodies 17026 for the lower thoracic spinal cord (gray matter, left; white matter, right). Dense
accumulation of tau was seen in the somatodentritic region of neurons as well as the cytoplasm and proximal processes of oligodendrocytes.
(B–D) High-power photomicrographs of neuron (B) indicated by arrow in (A) and oligodendrocytes (C and D) indicated by arrowheads in (A).
These oligodendrocytes were located in gray (C) or white (D) matter. (E–G) Double immunofluorescence stain for the glia cell in the spinal
cord of Tg mice. Tau (E) showed complete colocalization with CNP (F) in the cell body and proximal processes of an oligodendrocyte. (H–J)
Gallyas silver impregnation of glial tau pathology in the brain stem of 24-month-old Tg mice (H and I) and white matter of CBD frontal cortex
(J). Oligodentrocytes in old Tg mice developed Gallyas-positive fibrillary lesions (H and I) that resembled coiled bodies in human tauopathies
(J). (K) Immunostaining using anti-tau antibody 17026 in distal ventral roots of Tg mice. Strong immunoreactivity was found in some of the
axons and cells connected to the myelin sheaths. (L) High-power photomicrograph of the immunoreactive cells in the boxed area in (H). These
cells show morphological characteristics of Schwann cells. (M–P) Immunofluorescence staining of distal ventral root of Tg mice using antibodies
against S100 (M), human tau (T14) (N), and DAPI (O) with triple channel (P). Colocalization of tau and S100 indicates accumulation of transgenic
human tau in Schwann cells. Scale bars, 50 m (A); 20 m (B–G); 25 m (H–J); 50 m (K); and 10 m (L).
immunoreactive oligodendrocytes decreased with using antibodies against tau and S100 proteins (Figures
2M–2P).aging. Oligodendrocytic tau inclusions in young Tg mice
were negative for both Thioflavin-S and Gallyas silver Dense accumulations of tau also were observed in
the molecular layer of the cerebellum mostly in verticallystains, but they became positive for Gallyas silver im-
pregnation in the brain stem of Tg mice by 24 months oriented radial glial fibers of molecular layer (Figures 3A
and 3B). This pattern of tau staining is consistent with(Figures 2H and 2I). Since Gallyas silver staining detects
abnormal filaments, this result indicates that the accu- Bergman astrocytes, since a remarkable increase in glial
fibrillary acidic protein (GFAP) staining was detected inmulating tau proteins in oligodendrocytes progressively
form aggregates that resemble coiled bodies in human radial and stellate-shaped astrocytes in the same area
(Figures 3C and 3D). Further, triple immunofluorescencetauopathies such as CBD (compare Figure 2J with 2H
and 2I). Intense tau accumulation was also found in the staining demonstrated that the tau-immunoreactive ra-
dial fibers were not detected by an antibody to the neu-distal portion of the ventral roots (Figures 2K and 2L).
The tau proteins were located in the cytoplasm of small rofilament (NF) low molecular weight subunit (NFL) but
instead were derived from GFAP-positive astrocytescells surrounding the axons, and they were shown to be
Schwann cells by double immunofluorescence staining (Figures 3E–3H). These tau-positive astrocytic pro-
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Figure 3. Tau-Immunoreactive Astrocytes and Astrocytic Plaque-like Lesions in the Cerebellar Molecular Layer of Tg Mice
(A) Immunohistochemistry using mAb T14, showing numerous tau-positive radial processes throughout the cerebellar molecular layer of
6-month-old Tg mice. (B) High-power photomicrograph of the radial processes in the area marked by the square in (A). Several astrocyte-
shaped cells were also observed in this area. (C and D) Immunodetection of GFAP in cerebellar molecular layer of 6-month-old WT (C) and
Tg (D) mice showing reactive astrocytes in Tg compared to WT mice. (E–H) Triple immunofluorescence immunostaining showing the individual
localization of tau (E), GFAP (F), and NFL (G) as well as the colocalization using a triple channel (H) for the cerebellar molecular layer of
6-month-old Tg mice. Tau in the radial processes colocalized with GFAP but not with NFL. (I–L) Tau-positive inclusions form plaque-like
structures in the cerebellar molecular layer of 15-month-old Tg mice. Adjacent sections were stained with phosphorylation-independent tau
antibodies (17026, [I]), mAb against GFAP (2.2B10, [J]) and NFL (K), and phosphorylation-dependent tau antibodies (T3P, [L]). The tau-
immunoreactive plaque-like structure was partially positive for phosphorylated tau but negative for NFL. GFAP-immunoreactive astrocyte was
located at the center of this structure. (M–O) Tau inclusions in the plaque-like lesion were located in the distal processes of astrocytes, similar
to astrocytic plaques in the human CBD brain. (M) Triple immunofluorescence staining for plaque-like lesions in the cerebellar molecular layer
of 18-month-old Tg mice. Grain-shaped tau-immunoreactive inclusions (green, T14) partially colocalized with GFAP-immunoreactive astrocytic
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cesses appeared before 1 month of age and gradually Age-Related Progression of Tau Insolubility Is
Associated with Increase of Phosphorylated Tau thatdecreased in number with aging. The intensity of tau
Recapitulates PHF-Taustaining in each astrocytic process, however, showed
The formation of tau lesions in human tauopathies corre-a remarkable increase with age.
lates with aging and tau insolubility, and we demon-Significantly, the cerebellar molecular layer in Tg
strated increased insolubility of tau proteins with agingmice 12 months of age also showed a plaque-like
in the cerebellum and spinal cord of Tg mice (Figurepattern of tau immunoreactivities (Figure 3I) which con-
4A). For example, the amounts of RIPA- and FA-solublesisted of stippled tau inclusions. Immunohistochemical
fractions as percentages of total tau in 3-week-old Tganalysis using adjacent sections demonstrated that the
mice were 15% and less than 0.1%, respectively, butplaque-like lesions were not associated with NFL-posi-
they were increased to 22% and 1.3%, respectively, intive neuronal processes but with GFAP-positive astro-
18-month-old Tg mice. Although the neocortical sam-cytes (Figures 3I–3L). Furthermore, these tau inclusions
ples showed slight increases in RIPA-soluble fractionsin the Tg mice (Figure 3I) resembled astrocytic plaques
with aging, human and mouse tau proteins were notin CBD (Figure 3W). Association of the plaque-like struc-
detected in FA-soluble fractions.tures with astrocytes but not with neurons was also
In addition, phosphorylated tau proteins were de-demonstrated by double and triple immunofluorescence
tected in the FA-soluble fractions but not in the highstudies. As shown in Figure 3M, tau-positive inclusions
salt soluble and RIPA fractions, with different phosphor-partially colocalized with GFAP-positive astrocytic pro-
ylation-dependent anti-tau antibodies including PHF-1cesses, while no colocalization of tau and NFL was
(right panel in Figure 4B), PHF-6, T3P, AT8, AT270, andfound in the same lesion, but colocalization of tau and
12E8 (data not shown) and not by the non phosphoryla-GFAP was observed in the distal processes of astro-
tion dependent anti-tau antibody Tau1 (middle panel incytes (Figure 3N). Significant similarities were evident
Figure 4B). Furthermore, the phosphorylation state ofbetween the patterns of tau and GFAP within the plaque-
tau proteins in the FA-soluble fractions was similar tolike lesions in Tg mice (Figure 3N) and CBD brains (Figure
PHFs isolated from AD brain (Figure 4B), indicating that3O) by double immunofluorescence staining. The
the phosphorylation state of the FA-soluble tau in Tg
plaque-like structures were positive not only for phos-
mice recapitulated the phosphorylation of tau in human
phorylation-independent tau antibodies such as 17026
tauopathies. Significantly, the phosphorylated tau in FA-
(Figure 3I) but also for antibodies against phosphory-
soluble fractions detected by PHF-1 became more in-
lated tau, including T3P (Figure 3L), PHF-1, PHF-6, AT8, tense with aging (data not shown). This suggests that
and AT270 (data not shown). The tau-immunoreactive age-associated increases in tau phosphorylation corre-
inclusions in the plaques were also positive for Gallyas late with increased insolubility of tau in older Tg mice.
silver impregnation (Figures 3P–3R) and occasionally for
Thioflavin-S (Figures 3T–3V), suggesting that they were Progressive Loss of Neurons
comprised of abnormal filaments like astrocytic plaques and Glia Cells in Tg Mouse CNS
in CBD (Figure 3S). Finally, the plaques did not contain To assess the biological consequences of glial tau pa-
amyloid  peptides, since they were not detected by thologies, neurons in the anterior horn of the lumbar
antibodies (2332, 4G8, and BAN50) against A (data not spinal cord from Tg and WT mice at different ages were
shown). counted using cresyl violet-stained sections. As shown
The bigenic mice without endogenous mouse tau pro- in Figure 5A, age-related reductions in neurons were
teins that were generated by crossbreeding T1 Tg and more obvious in Tg mice than in WT mice, but significant
tau-KO mice did not show significant differences in the difference between Tg and WT mice was observed only
distribution of tau proteins from the single Tg mice (see in the oldest study group (18 months old). On the other
Supplemental Figures S1A–S1I at http://www.neuron. hand, tau-positive astrocytic plaque-like lesions emerged
org/cgi/content/full/35/3/433/DC1). Thus, the overex- at 12 months of age, and the number peaked at 15
pression of human tau proteins in these mice played a months (Figure 5B) and decreased thereafter in older
primary role in the formation of neuronal and glial tau animals. Similarly, tau-immunoreactive astrocytes in the
cerebellar molecular layer of Tg mice showed a trendpathologies.
processes (red) but not with NFL-positive neuronal processes (blue). (N) Double immunofluorescence labeling of the cerebellar molecular
layer sections of 18-month-old Tg mice showing that the central part of the plaque-like structure is poorly stained with T14 but contains a
GFAP-immunoreactive astrocyte. The grain-like tau inclusions colocalized partially with GFAP in the distal processes of the astrocyte. Red,
GFAP (2.2B10); green, tau (T14). (O) Double immunofluorescence of an astrocytic plaque in the mid frontal cortex of a human CBD brain
shows that the distribution of tau and GFAP are similar to the plaque-like lesion in the Tg mice. Red, GFAP (GFAP); green, tau (PHF-1). (P–V)
The Gallyas silver staining suggests that the plaque-like structures in both Tg mice and human CBD are composed of abnormal filaments.
Adjacent cerebellar molecular layer sections of 18-month-old Tg mouse were stained with antibodies against GFAP (GFAP, [P]) and tau
(17026, [Q]) and Gallyas silver impregnation (R). Tau-positive inclusions also are positive with Gallyas stain, similar to silver-stained astrocytic
plaque in CBD brain (S). Adjacent cerebellar molecular layer sections of a 18-month-old Tg mouse stained with antibodies against GFAP (T)
and tau (17026, [U]) and Thioflavin-S (V) demonstrated that the tau-positive inclusions in the plaque-like structure are partially positive with
Thioflavin-S, but the majority of the plaque-like structures in Tg mice and CBD brain do not show positive staining with Thioflavin-S. (W)
Astrocytic plaque in the mid frontal cortex of CBD brain stained with anti-tau antibodies 17026. The annular clusters of grain-shaped tau
inclusions resembled the tau inclusions forming the plaque-like structure in Tg mice (I). Scale bars, 200 m (A); 100 m (B–D); 100 m (E–H);
50 m (I–L); 50 m (M–O); and 50 m (P–W).
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abnormal filaments in oligodendrocytes were observed
in Tg mice24 months, we speculate that the accumula-
tion of tau in oligodendrocytes may lead to cell death
even before the formation of abnormal filamentous ag-
gregates.
Degeneration of Glia Cells and Disruption
of Compact Myelin in Tg Mice
Next, we performed transmission electron microscopy
(EM) and demonstrated degeneration of the oligoden-
drocytes and Schwann cells associated with severe my-
elin disruption in the spinal cord and ventral roots of
25-month-old Tg mice (Figure 6). For example, in the
ventral roots of Tg mice, there was significant thinning
of myelin sheaths compared with WT mice (compare
Figures 6A and 6B). Detachment of myelin layers was
common in old Tg mice but not in age-matched WT
mice (compare Figures 6A and 6B). In addition, structural
disorganization of myelin and consequent axonal de-
generation in Tg mice were associated with degenera-
tion of Schwann cells and migration of macrophages,
which showed accumulations of myelin debris, electron
dense bodies, and crystal-like deposits as well as nu-
merous lipid vacuoles (Figures 6C–6F). The compact
myelin in the spinal cord of old Tg mice also showed
prominent disorganization when compared with age-
matched WT mice (Figures 6G–6I). Finally, the degenera-
tion of glial cells and myelin sheaths in the spinal cord
Figure 4. Solubility and Phosphorylation State of Tau in Tg Mice and ventral roots of young Tg mice (6 months old) was
not as frequent when compared with old Tg mice, which(A) Proteins were sequentially extracted from the brain cortex, cere-
bellum, and spinal cord of 3-, 6-, 12-, and 18-month-old Tg mice is consistent with the age-related degeneration.
with RAB high-salt buffer, RIPA buffer, and 70% FA, immunoblot-
ted with the polyclonal antibodies 17026, and quantified using Formation of Tau Filaments in Glial Cells125I-labeled secondary antibodies. All the regions showed an in-
To determine whether or not tau accumulations led tocrease in the level of total tau between 3 weeks and 6 months.
filament formation in glial cells, immuno-EM micro-Progressive accumulations of RAB high-salt-insoluble tau that was
recovered from RIPA and FA fractions are observed in the cerebel- scopic studies were conducted showing accumulations
lum and spinal cord, whereas no remarkable changes in the solubility of tau in well-oriented tau filaments with diameter of about
of tau are found in cortex. 15–20 nm in the cytoplasm and processes of oligoden-
(B) Immunoblot analysis demonstrating that the phosphorylation drocytes of the brain stem from 6-month-old Tg mice
state of insoluble tau from Tg mice recapitulated that of PHF-tau.
(Figures 7A and 7B). Some of the oligodendrocytes inAutopsy-derived normal adult human tau and AD PHF-tau were
Tg mice contained inclusions that were densely packedimmunoblotted along with RAB high-salt-, RIPA-, and FA-extract-
able tau from 18-month-old Tg mouse cerebellum. Phosphorylation- with randomly oriented compact filamentous tau aggre-
independent antibodies 17026 reacted with total tau, and Tau1 and gates (Figures 7C and 7D). Accumulation of filamentous
PHF-1 recognized nonphosphorylated and phosphorylated tau pro- tau also was observed in the radial glial fibers of the
teins, respectively. cerebellar molecular layer of Tg mice (Figure 7E). Similar
to the tau filaments in oligodendrocyte processes, fila-
ments in astrocytic processes were15–20 nm in diam-of age-related decrease (data not shown). Thus, it is
eter. Most of the filaments observed in Tg mice werelikely that astrocytes overexpressing human tau were
straight and similar to those seen in the brains of alost during aging.
FTDP-17 patients with an intronic16 tau gene mutationIn contrast to neurons, oligodendrocytes in Tg mice
(compare Figure 7E with 7F). Old Tg mice also showedshowed prominent reductions at earlier ages. As indi-
dense tau inclusions in oligodendrocytes and astro-cated in Figure 5C, total CNP-positive oligodendrocytes
cytes. However, the filamentous tau accumulations inin the lumber spinal cord of Tg mice were significantly
old Tg mice were less frequent than in 6-month-old Tgless than in WT mice at 6 months of age, and this loss
mice, but more extensive glial degeneration was de-of oligodendrocytes paralleled the loss of tau-immuno-
tected.reactive oligodendrocytes with aging. Indeed, the differ-
ence in the number of total CNP-positive oligodendro-
cytes between 1- and 18-month-old Tg mice (40/section) Progressive Motor Weakness
The Tg mice developed progressive motor weakness,was quite similar to the difference in the number of tau-
immunoreactive oligodendrocytes seen in the same Tg including impaired ability to stand on a slanted surface
and dystonic movement of the hindlimbs or both hind-mice (35/section). This implies that the loss of oligoden-
drocytes in Tg mice resulted primarily from the loss limbs and forelimbs when lifted by their tails (Figure 8).
At the age of 6 months, approximately 5% of WT andof tau-positive oligodendrocytes. Since Gallyas-positive
Glial Tauopathy in Tau Transgenic Mice
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Figure 5. Quantitative Analyses Showing
Age-Related Changes in the Histopathologi-
cal Findings
(A) Mild progressive decrease in the anterior
horn neurons of the Tg mouse spinal cord.
The neurons were counted using cresyl vio-
let-stained sections.
(B) Emergence of astrocytic plaque-like le-
sions in the cerebellar molecular layer of the
Tg mice. The tau-immunoreactive plaque-like
structures were observed from the age of 12
months and peaked at 15 months. Sections
stained with anti-tau antibodies 17026 were
used for the quantification.
(C) Marked decrease in the CNP- and tau-
immunoreactive oligodendrocytes of the Tg
mouse spinal cord with aging. The human
tau-specific T14 antibody was used for
counting the tau-positive oligodendrocytes.
The reduction of CNP-immunoreactive oligo-
dendrocytes corresponded to the reduction
of tau-immunoreactive oligodendrocytes.
Vertical bar indicates SE. *p 	 0.05; **p 	
0.01.
Tg mice showed limb twitch (n 
 20 in each group). 1998b; Goedert et al., 1999; Delisle et al., 1999; Iseki et
al., 2001). In contrast, the oligodendrocytic inclusionsHowever, at 24 months of age, limb twitch was observed
in multiple system atrophy (MSA) are formed byin 72% of Tg mice, compared with 18% of WT mice (n

-synuclein, but they also are variably tau positive (Chin11 in each group, p 
 0.03 by 2 test) (Figure 8). These
and Goldman, 1996; Tu et al., 1998). Finally, the detec-progressive motor deficits in Tg mice could reflect the
tion of widespread and abundant glial tau pathologiesage-related increase of myelin degeneration in both CNS
in several forms of human tauopathies by immunohisto-and PNS.
chemistry has been confirmed biochemically, and it is
increasingly clear that insoluble tau in white matter isDiscussion
often more abundant than that in gray matter of some
tauopathies, such as PiD and CBD (Forman et al., 2002;
Here, we report the generation of a tau Tg mouse model
Zhukareva et al., 2002). These observations suggest that
of FTD that developed glial tau pathologies. Notably,
glial tau pathologies play important roles in the patho-
progressive accumulations of tau in astrocytes and oli-
genesis of FTDs, and our T1-3RT tau Tg mouse models
godendrocytes were closely associated with degenera-
provide experimental credence for this notion.
tion of these cells as well as with disruption of myelin
The glial tau pathologies are most abundant in the
sheaths. Aged Tg mice showed numerous glial tau inclu- cerebellum, spinal cord, and brain stem. Although tau
sions composed of Gallyas silver-positive abnormal fi- pathologies are commonly observed in brain stem and
bers. These glial inclusions were morphologically, histo- spinal cord of Tg mouse models of tauopathies (Ishihara
chemically, and immunohistochemically similar to the et al., 1999; Spittaels et al., 1999; Probst et al., 2000,
glial tau pathologies in FTDs, such as PSP, PiD, PSG, Lewis et al., 2000), such pathology has not been ob-
CBD, and FTDP-17. served in the cerebellum. The development of glial tau
The importance of glial pathology in human tauopa- lesions in the cerebellum is most likely due to high tau
thies has been under appreciated until recently because expression driven by the tubulin T1 promoter employed
most earlier studies of tau pathology focused on AD in this study. Significantly, glial tau pathologies in the
wherein glial tau inclusions are uncommon (Iwatsubo et spinal cord and cerebellum have recently been reported
al., 1994; Nishimura et al., 1995). However, studies of in human tauopathies, such as amyotropic lateral sclero-
PSP, CBD, and PiD revealed significant glial tau patholo- sis-parkinsonism dementia complex of Guam (Oyanagi
gies (Chin and Goldman, 1996; Dickson et al., 1996; et al., 1997), PSP, and CBD (Piao et al., 2002).
Komori, 1999) and we show here that our T1-3RT tau In addition to morphological and immunohistochemi-
Tg mice model relevant features of these glial tau le- cal similarities between authentic glial tau lesions in
sions. For example, astrocytic glial fibrillary tangles FTDs and those in our tau Tg mice, there was increased
(GFTs) as well as oligodendrocytic GFTs are common tau phosphorylation and insolubility just like human tau-
in CBD (Feany and Dickson, 1995; Komori et al., 1998), opathies. Significantly, increased tau phosphorylation
PiD (Yamazaki et al., 1994; Feany et al., 1996), and PSP and insolubility also were observed in tau Tg mice over-
(Nishimura et al., 1992; Yamada et al., 1992; Komori et expressing human WT and mutant tau isoforms that
al., 1998), and similar lesions were detected in our Tg develop neuronal tau inclusions (Ishihara et al., 1999;
mice. In addition, tau-positive oligodendrocytic pro- 2001; Lewis et al., 2000; Spittaels et al., 1999), and similar
cesses and astrocytic plaques are abundant in CBD hyperphosphorylated, insoluble tau proteins are promi-
(Feany and Dickson, 1995; Komori et al., 1998) and some nent in human tauopathies characterized by neuronal
and glial tau inclusions (Lee et al., 1991; Iwatsubo et al.,FTDP-17 cases (Reed et al., 1997; Spillantini et al.,
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Figure 6. Transmission Electron Micrographs, Demonstrating Myelin Degeneration Associated with Glial Degeneration in the Spinal Cord and
Ventral Roots of 25-Month-Old Tg Mice
(A and B) Ventral root nerve fibers of the Tg (B) and age-matched WT control mice (A). Tg mice show profound reduction of myelin thickness,
detachment of myelin layers from axons (arrows), and severe loss of compact myelin associated with migration of macrophages (arrowheads).
(C) High-power photomicrograph of the area indicated by arrowhead in (B). A putative macrophage (m) containing large amount of myelin
debris is in contact with a demyelinated axon (a). (D) High-power photomicrograph of the area indicated by arrowhead in (B). A putative
macrophage (m) laden with myelin debris and crystal-like deposits (arrows) is closely associated with a Schwann cell (Sc). The myelin sheath
surrounding an axon (a) shows reduced thickness. (E and F) Accumulations of numerous lipid vacuoles and myelin debris-containing bodies
are observed in the putative macrophages (m) closely apposed to axons (a), and the compact myelin surrounding the axons shows thinning.
(G) Unlike WT mice, multilaminar bodies and dissociation of the myelin layers were frequently found in the Tg mouse spinal cord. Arrowhead
indicates the oligodendrocyte nucleus. (H) Detachment of myelin layers in the Tg mouse spinal cord. (I) High-power photomicrograph of (H)
with degenerated myelin layers indicated by arrowheads. Scale bar, 2 m (A, B, G, and H); 500 nm (C–F); and 1 m (I).
1994; Dickson et al., 1996; Forman et al., 2002; Zhukar- three human 3RT tau isoforms expressed in the tau Tg
mice was different from that in the normal human brain.eva et al., 2002).
The T1-3RT Tg mice were developed initially to drive The reasons for this are unclear, but it may be due to the
deletion of intronic sequences that regulate alternativeexpression of all six tau isoforms in mice with the expec-
tation of developing tau pathologies, since humans ex- splicing or reflect differences in splicing mechanisms in
the mouse and human tau genes. Indeed, the develop-press all six tau isoforms, but mice express only 4RT
isoforms, and only humans spontaneously develop tau ment of tau transgenic mice using a 100 kb YAC clone
containing the entire tau gene showed that alternativelesions. Since some forms of FTDP-17 result from muta-
tions that alter tau gene splicing and perturb the normal splicing of the tau gene in rodents and humans is quite
different (M.H. et al., unpublished data).brain tau isoform composition, a second reason for cre-
ating the T1-3RT Tg mice was that we could examine However, it is unlikely that an imbalance of the tau
isoform composition in our tau Tg mice is responsiblethe biological consequences of an abnormal ratio of tau
isoform ratio in our single Tg mice as well as in T1- for the neurodegenerative tauopathy we observed for
several reasons. First, Tg mice overexpressing a single3RT  tau-KO bigenic mice. Notably, the ratio of the
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Figure 7. Immunoelectron Microscopy Dem-
onstrates Filamentous Tau Accumulation in
the Glia Cells of 6-Month-Old Tg Mice
Anti-tau polyclonal antibodies 17026 were
used. (A) Accumulation of tau in the cyto-
plasm and processes of brain stem oligoden-
drocyte. (B) High-power photomicrograph of
the boxed area in (A), showing tau filaments in
the process of a oligodendrocyte. (C) Dense
accumulation of tau in a brain stem oligoden-
drocyte. (D) High-power photomicrograph of
the tau inclusion indicated by the square in
(C). (E) Astrocytic process in the cerebellar
molecular layer showing filamentous tau ac-
cumulation. The filaments ranged from 10 to
15 nm in diameter. (F) Tau filaments observed
in the oligodendrocyte of frontal cortex from
a FTDP-17 patient with an intronic 16 tau
gene mutation. The tau-immunolabeled fila-
ments ranged from 10 to 15 nm in diameter,
similar to the filaments found in the glia cells
of Tg mice. Scale bar, 2 m (A and C); 500
nm (B and D); and 250 nm (E and F).
WT tau isoform do not develop tau pathology unless tau subtle, and there are conflicting data on apoptosis in
glial cells in human tauopathy brains (Matsuo et al.,is massively overexpressed (Go¨tz et al., 1995; Ishihara
et al., 1999; Spittaels et al., 1999, Probst et al., 2000). 1998; Gleckman et al., 1999). Thus, no previous studies
have implicated glial tau inclusions in the degeneration,Second, tau Tg mice expressing the entire 100 kb human
tau gene also do not develop tau pathology. Finally, and our data demonstrate a close association between
progressive accumulations of abnormal tau in glial cellscrossbreeding the T1-3RT Tg mice with tau-KO mice
did not influence the tau pathology, suggesting that ov- and gliodegeneration including a loss of oligodendro-
cytes and myelin disruption. Interestingly, gliodegenera-erexpressing the human tau proteins alone was suffi-
cient to induce a glial tauopathy. tion most likely occurs prior to the emergence of the
argyrophilic coiled bodies and astrocytic plaques, sinceAlthough accumulation of tau inclusions in glia cells
may lead to degeneration of affected cells, it is unclear we observed degeneration of glial cells in 6-month-old
Tg mice. Thus, gliodegeneration may begin due to thehow this might occur. A previous study has shown that
filamentous tau accumulates in oligodendrocytes of Tg accumulation of tau protofibrils and loosely packed tau
filaments that are Gallyas and Thioflavin-S negativemice overexpressing the G272V tau mutant (Go¨tz et al.,
2001b), but the clinical phenotype in these mice was rather than when GFTs develop. This finding still remains
Neuron
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Figure 8. Limb-Twitching Phenotype of the WT and Tg Mice
The mice were lifted by their tails for 10 s, and a dystonic movement
of the extremities was examined. The frequency of the limb twitch
was calculated for the WT and Tg mice at each age. Significant
difference in the frequency between the WT and Tg mice was ob-
served at the age of 24 months (p 
 0.03 by 2 test). n 
 20,
20, 20, 13, and 11 in each group at 1, 6, 12, 18, and 24 months,
respectively.
an issue, since some oligodendrocytes but not others
survived until the formation of argyrophilic inclusions.
Indeed, most of the oligodendrocytes in the spinal cord
died before they developed Gallyas-positive lesions,
while those in brain stem showed only modest reduc-
tions and produced Gallyas-positive coiled body-like
tau inclusions. Although the reasons for the divergence
in glial survival under the influence of tau accumulations
remain unclear at this time, they might be due to differ-
ences in human tau expression levels and/or selective
vulnerability of oligodendrocytes in different CNS re-
gions. Also, the temporal difference in the onset or com-
pletion of oligodendrocytic differentiation also contrib-
ute to variations in the accumulation of tau during the
progressive maturation and aging of these cells.
In addition to the distinct glial pathologies, our Tg mice
developed increased neuronal tau immunoreactivities in
multiple CNS areas, including neocortex, hippocampus,
brain stem, and spinal cord (see Table 1 for more details).
However, unlike previous Tg mice overexpressing hu-
man tau in neurons that developed tau tangles and
spheroids concomitant with axonpathy and muscle
weaknesses (Ishihara et al., 1999; 2001; Lewis et al.,
2000; Go¨tz et al., 2001b), neuronal inclusions were not
present in the T1-3RT Tg mice. In this regard, the so-
mato-dendritic tau immunoreactivities in these mice re-
sembled pretangles that were detected in Tg mice with
low human tau expression in the absence of any clinical
phenotype (Go¨tz et al., 1995, Brion et al., 1999). Thus,
we conclude that the motor deficits and myelin degener-
ation observed in our Tg mice most likely are conse-
quences of glial tau lesions and not neuronal tau accu-
mulation.
Although cellular mechanisms of gliodegeneration as
a consequence of tau accumulation still need to be clari-
fied, our study suggests several pathogenic processes
that may compromise the viability and functions of glial
cells. For example, excess human tau proteins in
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astrocytes may disrupt the cytoskeletal network, leading
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incubated with Escherichia coli alkaline phosphatase (Sigma) atto a collapse of MTs and intermediate filaments since we
37C overnight as described elsewhere (Hong et al., 1998). Equalobserved that the tau inclusions and GFAP only partially
amounts (15 g) of non-dephosphorylated and dephosphorylatedcolocalized within astrocytic plaques of CBD, and our
protein samples were subsequently resolved on 7.5% SDS-PAGE
tau Tg mice, while GFAP can be detected in proximal gels and transferred onto nitrocellulose membranes. Either
and distal processes of normal astrocytes. Tau aggre- 125I-labeled goat anti-mouse IgG or 125I-labeled Protein A (NEN) was
used as secondary antibodies to perform the quantitative Westerngates also are likely to perturb the cytoskeletal network
blot analysis as described previously (Ishihara et al., 1999).in oligodendrocytes, since tau is known to promote MT
assembly and stabilize MTs in oligodendrocytes (Rich-
Analysis of Tau Protein Solubility and Phosphorylation Statester-Landsberg, 2001). Further, tau aggregates could be
in the Tg Mouse CNStoxic and lead to the degeneration of affected cells.
Proteins were extracted from the neocortex, cerebellum, and spinal
To summarize, the Tg mice described here demon- cord of 3-week, 6-, 12-, and 18-month-old Tg mice using RAB-HS
strate the potential roles of abnormal tau accumulation as described above. The RAB-HS-insoluble pellets were rehomoge-
in the pathogenic processes of glial tauopathy. Hence, nized with 1 M sucrose in RAB (0.1 M MES, 1 mM EGTA, and 0.5
mM MgSO4 [pH 7.0]) and centrifuged at 40,000  g for 20 min atthese mice will provide useful tools to investigate the
4C to remove myelin and associated lipids. The resulting pelletspathological impacts of progressive gliodegeneration in
were dissolved with 1 ml/gm radioimmunoprecipitation assay bufferdiverse human tauopathies, including PSP, CBD, PSG,
(RIPA) [50 mM Tris, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxy-
PiD, FTDP-17, MSA, and AD. cholate, 1% NP40, 5 mM EDTA [pH 8.0]) and centrifuged at 40,000
g for 20 min at 4C. The supernatants were used as RIPA-soluble
samples. The RIPA-insoluble pellets were extracted with 70% formicExperimental Procedures
acid (FA) to recover the most insoluble cytoskeletal aggregates.
Quantitative Western blot analyses were performed with humanGeneration of Tau Tg Mice
adult tau control samples as described previously (Lee et al., 1991;A minigene construct of human tau that is capable of producing
Bramblett et al., 1992, 1993).three human brain tau isoforms with 3RT was created in pKS vector
by embedding a modified genomic version of tau exons 1 to 4
(containing introns that flank exons 2 and 3) in a cDNA for the Immunohistochemical and Histochemical Studies
shortest tau isoform (exons 1 to 13 without exons 4A, 6, 8, and Mice were transcardially perfused with 15 ml of phosphate-buffered
10). The tubulin T1 promoter was cloned into pcDNA3 vector, and saline (PBS) followed by 15 ml of either 70% ethanol in isotonic
the XmnI site on pcDNA3 was modified to an AscI site. Transgenic saline or 4% paraformaldehyde in PBS after they were deeply anes-
construct (T1-3RT) was made by ligating a SalI/PvuII fragment thetized. Representative 6 m thick paraffin sections of the brains,
of the minigene construct into a KpnI/NotI-fragment of the T-1 spinal cords, and ventral root nerves were immunostained using
promoter vector. The T1-3RT was cut with AscI, purified, microin- standard streptavidin-biotin-peroxidase methods as described
jected into fertilized B6SJL/F1 mouse eggs, and reimplanted into (Ishihara et al., 1999). Double- and triple-labeling immunofluores-
pseudopregnant females. Genomic DNA samples were isolated from cence studies were conducted to determine the colocalization of
mouse tails with the Puregene (Gentra Systems) DNA isolation kit, different cytoskeletal components. In addition, Gallyas silver and
and samples were screened by Southern blot analysis with a 32P- Thioflavin S histochemical stains were performed to detect abnor-
labeled KpnI/NotI-fragment of the transgene vector. Three stable mal fibrillary lesions on the sections (Gallyas, 1971).
Tg mouse lines (lines 13, 14, and 22) expressing the transgene and To detect the oligodendrocytes, the mice were serially perfused
human tau proteins were obtained. Because it was not possible to with 10 ml of PBS, 25 ml of 3% paraformaldehyde in 0.1 M phosphate
generate homozygous line 14 mice, we studied heterozygous line 14 buffer (PB) (pH 7.5), 25 ml of 3% paraformaldehyde in 50 mM sodium
Tg mice because they expressed the highest levels of the transgenic borate buffer (pH 9.0), and 30 ml of 10% sucrose in 0.1 M PB. Brains
human tau proteins. and spinal cords were removed and stored at 4C in 50 mM PB
In order to determine if the presence of endogenous mouse tau containing 25% sucrose and 10% glycerol for cryoprotection (Li et
influences biochemical and histopathological characteristics of the al., 1997). Sections (15m thick) of frozen brain and spinal cord were
human tau transgene in our animals, Tg mice lacking endogenous double labeled by immunofluorescence using antibodies against tau
tau were generated by crossbreeding T1-3RT Tg mice (line 14) and CNP, an oligodendrocytes marker.
with tau-KO mice. The tau-KO mice were obtained from Dr. Vitek, Neurons in the anterior horn of the lumber spinal cord were
Duke University (Dawson et al., 2001), and screened by PCR with counted using 5m thick paraffin sections stained with cresyl violet.
primers for exon 1 of mouse tau gene (5-GCTGAACACTCATTGA Tau-immunoreactive and CNP-immunoreactive oligodendrocytes in
GACTGGGC-3 and 5-TGTTGTAAGGTATGAACAACTCC-3) that the lumber spinal cord were also counted using double-immunola-
generated a 416 bp product. beled 15 m thick frozen sections.
For the above-mentioned immunohistochemical and immuno-
chemical analyses, the Tg and WT mice aged 1, 3, 6, 9, 12, 18, andWestern Blot Analysis of Tau Protein Expression
24 months were examined. Sections were obtained from at leastin the Mouse CNS
three Tg and WT mice at each age, and 20 sections from eachLevels of the transgenic human tau and endogenous mouse tau in
mouse were examined.different CNS regions of line 14 Tg and WT mice were determined
using immunoblot analyses as described (Ishihara et al., 1999). The
brain and spinal cord were dissected from mice after they were Transmission Electron Microscopy
In order to assess the degeneration of neurons and glia cells at anlethally anesthetized in accordance with protocols approved by Uni-
versity of Pennsylvania University Laboratory Animal Research. The ultrastructural level, transmission EM was performed for the Tg and
WT mice at 6, 12, 18, and 25 months of age (n 
 2 at each age).tissue samples were homogenized in 2 ml/gm ice-cold high-salt
reassembly buffer (RAB-HS) (0.1 M MES, 1 mM EGTA, 0.5 mM These mice were deeply anesthetized and intracardially perfused
with 10 ml of 0.1 M cacodylate buffer (pH 7.4) containing 0.05%MgSO4, 0.75 M NaCl, 0.02 M NaF, 1 mM PMSF, and 0.1% protease
inhibitor cocktail [100 g/ml each of pepstatin A, leupeptin, N-tosyl- glutaraldehyde and 0.5% paraformaldehyde, followed by 50 ml of
0.1 M cacodylate buffer containing 2% glutaraldehyde and 2% para-L-phenylalanyl chloromethyl ketone, N-tosyl-lisine chloromethyl ke-
tone, soybean trypsin inhibitor, and 100 mM EDTA] pH 7.0) and formaldehyde. The brain and L5 segments of the spinal cord and
ventral root were removed and postfixed in 2% osmium tetroxide forcentrifuged at 40,000  g for 40 min at 4C in the Beckman TL-100
ultracentrifuge. The supernatants were boiled for 5 min, chilled on 60 min at 4C. After dehydration with graded alcohol and propylene
oxide, the tissues were embedded in Epon-812 and polymerized atice for 5 min, and recentrifuged at 13,000  g for 20 min at 4C.
Protein concentration was measured for the second supernatants 60C for 72 hr. Sections (65 nm thin) were cut and mounted on
200 mesh copper grids. The sections were stained with 1% uranylwith the BCA assay kit (Pierce). An aliquot of the supernatant was
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acetate in 50% ethanol and bismuth subnitrate and examined with Ser396 in Alzheimer’s disease recapitulates development and con-
tributes to reduced microtubule binding. Neuron 10, 1089–1099.a JEM1010 electron microscope (Jeol) at 80kV.
Brion, J.P., Tremp, G., and Octave, J.N. (1999). Transgenic expres-
Pre-Embedding Immunoelectron Microscopy sion of the shortest human tau affects its compartmentalization and
To study the distribution and organization of the cytoskeletal com- its phosphorylation as in the pretangle stage of Alzheimer’s disease.
ponents, pre-embedding immunoelectron-EM was performed in the Am. J. Pathol. 154, 255–270.
Tg and WT mice aged 6 and 25 months (n 
 4). Animals were
Carden, M.J., Trojanowski, J.Q., Schlaepfer, W.W., and Lee, V.M.-Y.perfusion fixed as described above except that buffer containing
(1987). Two-stage expression of neurofilament polypeptides during0.2% instead of 2% glutaraldehyde was used. The brain and L5
rat neurogenesis with early establishment of adult phosphorylationsegments of the spinal cord and ventral root were removed and
patterns. J. Neurosci. 7, 3489–3504.postfixed in 0.1 M cacodylate buffer containing 4% paraformalde-
Chin, S.S.-M., and Goldman, J.E. (1996). Glial inclusions in CNShyde, 0.2% glutaraldehyde, and 0.2% picric acid overnight. Prepara-
degenerative diseases. J. Neuropathol. Exp. Neurol. 55, 499–508.tion and staining of tissue sections for immuno-EM was conducted
as previously described (Ishihara et al., 1999) using primary anti- Clark, L.N., Poorkaj, P., Wszolek, Z., Geschwind, D.H., Nasreddine,
tau 17026 (1:500) or anti--tubulin (1:100) antibodies. Immuno-EM Z.S., Miller, B., Li, D., Payami, H., Awert, F., Markopoulou, K., et al.
was also performed for brain tissue from an FTDP-17 patient with (1998). Pathogenic implications of mutations in the tau gene in pal-
an intronic 16 tau gene mutation. The white matter adjacent to lido-ponto-nigral degeneration and related neurodegenerative dis-
the frontal cortex showed abundant tau-immunoreactive coiled bod- orders linked to chromosome 17. Proc. Natl. Acad. Sci. USA 95,
ies in oligodendrocytes, and thus, sections obtained from this region 13103–13107.
were processed as described above in order to compare oligoden-
Dawson, H.N., Ferreira, A., Eyster, M.V., Ghoshal, N., Binder, L.I.,drocytic tau filaments in Tg mouse and human tauopathy. The sec-
and Vitek, M.P. (2001). Inhibition of neuronal maturation in primarytions were then examined as described above.
hippocampal neurons from tau deficient mice. J. Cell Sci. 114, 1179–
1187.Antibodies
Delisle, M.B., Murrell, J.R., Richardson, R., Trofatter, J.A., Rascol,The following phosphorylation-dependent and -independent anti-
O., Soulages, X., Mohr, M., Calvas, P., and Ghetti, B. (1999). A muta-tau antibodies were used in the present study. Phosphorylation-
tion at codon 279 (N279K) in exon 10 of the Tau gene causes aindependent antibodies include monoclonal antibody (mAb) T46 and
tauopathy with dementia and supranuclear palsy. Acta Neuropathol.T14 (specific to human tau) (Kosik et al., 1988); rabbit polyclonal
(Berl). 96, 8229–8234.antibodies 17026 made against the recombinant protein of the lon-
gest human tau isoform (Ishihara et al., 1999); and mAb T49 (specific Dickson, D.W., Feany, M.B., Yen, S.H., Mattiace, L.A., and Davies,
to mouse tau) (Mawal-Dewan et al., 1994). Phosphorylation-depen- P. (1996). Cytoskeletal pathology in non-Alzheimer degenerative de-
dent antibodies include mAb T1 (Binder et al., 1985; Szendrei et al., mentia: new lesions in diffuse Lewy body disease, Pick’s disease,
1993); mAb PHF1 (Greenberg and Davies, 1990; Lang et al., 1992; and corticobasal degeneration. J. Neural Transm. Suppl. 47, 31–46.
Otvos et al., 1994); mAb PHF6 (Hoffmann et al., 1997); mAb AT8
D’Souza, I., Poorkaj, P., Hong, M., Nochlin, D., Lee, V.M.-Y., Bird,(Goedert et al., 1994; Matsuo et al., 1994); mAb AT270 (Goedert et
T.D., and Schellenberg, G.D. (1999). Missense and silent tau geneal., 1994; Matsuo et al., 1994); mAb 12E8 (Seubert et al., 1995); and
mutations cause frontotemporal dementia with parkinsonism-chro-rabbit polyclonal antibodies T3P (Lee et al., 1991). The following
mosome 17 type, by affecting multiple alternative RNA splicing regu-antibodies against neurofilament (NF) subunits were used: mAb
latory elements. Proc. Natl. Acad. Sci. USA 96, 5598–5603.RmdO9 against nonphosphorylated NFH; mAb RMO 24 against
Feany, M.B., and Dickson, D.W. (1995). Widespread cytoskeletalphosphorylated NFH; RMO189 against phosphorylation-indepen-
pathology characterizes corticobasal degeneration. Am. J. Pathol.dent NFM (Carden et al., 1987); a rabbit polyclonal antibody against
146, 1388–1396.NFL (Tu et al., 1995). The anti-A antibodies included 2332 (Szendrei
et al., 1996), 4G8 (Kim et al., 1990), and BAN50 (Suzuki et al., 1994). Feany, M.B., Mattiace, L.A., and Dickson, D.W. (1996). Neuropatho-
Other antibodies used were mouse mAbs against -tubulin (Santa logic overlap of progressive supranuclear palsy, Pick’s disease and
Cruz), -tubulin (Sigma), CNP (Chemicon) and ubiquitin (Chemicon), corticobasal degeneration. J. Neuropathol. Exp. Neurol. 55, 53–67.
rat mAb (2.2B10, Lee et al., 1984), and a rabbit polyclonal antibody
Forman, M.S., Zhukareva, V., Bergeron, C., Chin, S.S.-M., Grossman,(GFAP, DAKO) against GFAP. Rabbit polyclonal antibodies against
M., Clark, C., Lee, V.M.-Y., and Trojanowski, J.Q. (2002). Signatureanti-bovine S100 (DAKO), which also react with mouse S100, were
tau neuropathology in gray and white matter of corticobasal degen-used as well.
eration. Am. J. Pathol. 160, 2045–2053.
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